Ras

Ras inhibitors and related small GTPase modulators act on KRAS and on the Rac, Rho and Cdc42 proteins. Small GTPases of the Ras superfamily work as molecular switches. They cycle between an active form bound to guanosine triphosphate (GTP) and an inactive form bound to guanosine diphosphate (GDP). Oncogenic KRAS mutations such as G12C keep the protein in its signaling state. ARS-853 and KRas G12C inhibitor 4 target the mutant cysteine of KRAS G12C, while Kobe2602 interferes with binding of Ras to Raf. Salirasib, a farnesylcysteine mimetic, disrupts the membrane association of Ras. Rho-family tools include NSC 23766 and EHT 1864, which inhibit Rac, and CASIN, which targets Cdc42.

6 Items

  • RGB-1
    Cat. No.
    A24804

    RGB-1

    RGB-1 is a selective RNA G-quadruplex stabilizer that targets and reduces the expression of the NRAS proto-oncogene within breast cancer cells. This compound serves as a valuable tool for exploring the cellular mechanisms and functions of RNA G-quadruplex structures, while also aiding in the identification of novel mRNA sequences capable of forming G-quadruplexes. RGB-1 is particularly relevant for research focused on breast cancer therapeutics and the molecular basis of oncogene regulation.

    1 mg
    $300.00
    5 mg
    $765.00
    All 3 sizes
  • KRA-533
    Cat. No.
    A63527

    KRA-533

    KRA-533 is a potent KRAS agonist that selectively binds to the GTP/GDP binding pocket of the KRAS protein. This interaction inhibits GTP cleavage, leading to the accumulation of constitutively active GTP-bound KRAS. Consequently, KRA-533 induces both apoptotic and autophagic cell death pathways in cancer cells, making it a valuable tool for research into cancer biology and therapeutic strategies targeting KRAS signaling.

    2 mg
    $25.00
    5 mg
    $45.00
    All 7 sizes
  • I942
    Cat. No.
    A63539

    I942

    I942 is a selective non-cyclic nucleotide (NCN) agonist of EPAC1. It effectively modulates proinflammatory cytokine signaling pathways associated with various cardiovascular diseases. This compound serves as a valuable tool in research focused on understanding EPAC1-related mechanisms and developing therapeutic strategies for inflammatory cardiovascular conditions.

    1 mg
    $75.00
    5 mg
    $195.00
    All 7 sizes
  • PPI stabilizer-1
    Cat. No.
    A63664

    PPI stabilizer-1

    PPI stabilizer-1 is a KRAS dimerizing agent that effectively promotes the dimerization of KRAS with a dissociation constant (KD) of 3.8 µM. This compound has the ability to co-crystallize with GCP-KRASG12D, facilitating structural studies and elucidating the role of KRAS in cellular signaling. PPI stabilizer-1 is valuable for researching KRAS-driven cancers, providing insights into therapeutic strategies targeting this critical pathway.

    Out of stock

    All 3 sizes
  • JH530
    Cat. No.
    A63722

    JH530

    JH530 is a potent inducer of methuosis, specifically targeting triple-negative breast cancer (TNBC) cells. It triggers extensive intracellular vacuolization, leading to the inhibition of TNBC cell proliferation. With its demonstrated anti-tumor activity, JH530 serves as a valuable tool for cancer research applications.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • 8-pHPT-2'-O-Me-cAMP
    Cat. No.
    A63794

    8-pHPT-2'-O-Me-cAMP

    Synonyms: 8-(4-Hydroxyphenylthio)-2'-O-Me-cAMP

    8-pHPT-2'-O-Me-cAMP is a cAMP analog that acts as an Epac agonist, specifically enhancing the activity of the exchange protein activated by cyclic AMP (Epac). This compound is utilized in cardiac research to explore signaling mechanisms and cellular responses associated with cardiac function and pathophysiology. Its ability to modulate Epac pathways makes it a valuable tool for investigating the roles of cAMP in cardiac health and disease.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

6 Items

Added to your cart

View Cart Checkout

    Loading...